|
||
| |||||||
|
Parkinson's disease (PD) is a non-curable chronic progressive ailment that affects 1% of the population over the age of fifty and haunts its sufferers for an average of 13 years. As the disease increase in severity over the years so does the patient's medications need. The last decades have been characterized by impressive research activity in connection with Parkinson's disease. A wealth of new results have enriched our knowledge of the pathophysiology of the disorder and led to new approaches for its management. Current research in brain neurotransmitters and cell therapy promises a cure in the near future with dramatic implications for both the patients and the companies that serve them. Demographic trends, increasing levels of environmental pollution and the rise in the number of drug abusers are all contributing factor for the rise in numbers of Parkinson's disease sufferers which currently stands at 2 million in the developed world alone. The current market for Parkinson's disease is highly fragmented and looks like the antidepressant market before the launch of Prozac. However, through the adoption of innovative disease management strategies the market has the potential of reaching annual revenue of over $2.4 billion by 2007. The introduction of newer therapies and the switch to novel drug delivery formulation of established therapeutics is raising the average cost of therapy for managing the disease which is encouraging drug companies to rethink their strategies regarding the market. Parkinson's Disease, State-of-the-Science & Strategic Opportunities is a strategic consulting report that assesses both the technology status and the competitive landscape of the Anti-Parkinson medications market. The report examines both the US and the European markets in detail, profiles leading products and companies and offers revenue forecasts to the year 2007. The report assesses the market attractiveness and potential and evaluates different options for market entry. Report Code: 0301AS1N Date Published: November 2002 Number of Pages: 35 Publisher: AS Insights Opportunity and Valuation Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a39
|
|
| ||||||||